|
|
Patients who were given this medication recorded a greater reduction in antihistamine use after the treatment than those given a placebo. this medication is free from drowsy side effects. What colloidal this medication Patients Say What Patients Said After More Than silver and therapies One Year In 11 years of service to my company, this is the first year I worked without a day of sick colloidal time. Jaime C. Allergies seem to be excellent this year. Thanks for the study. Robin S In 1995, I got by very well. Ben H. I experienced fewer problems...since I participated in the study. Evea J. I always woke up congested and would sneeze like crazy when I mowed the lawn. Since I was treated, my allergy symptoms have gone away completely. E. A. What Patients Said After More Than Six Months Allergies are much better than before. Michael G. silver I am the best! George G. Feel a lot better than last year. Mark B. I am doing a great deal better Louis P. Antihistamines As the name indicates, an antihistamine counters therapies the effects of histamine, which is released by the mast cells in the body''s tissues and contributes to allergy symptoms. For many years, colloidal antihistamines have proven useful in relieving sneezing and itching in the nose, throat, and eyes and in reducing nasal swelling and drainage. Many people who take antihistamines experience some distressing side effects: drowsiness and loss of alertness and coordination. In children, such reactions can be misinterpreted as behavior problems. During the last few years, however, antihistamines that cause fewer of these side effects have become available by prescription. These new nonsedating antihistamines are as effective silver as other antihistamines in preventing histamine-induced symptoms, therapies but do so without causing sleepiness. Patients gave blood serum samples prior to the treatment in 1992 and one year later in 1993. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=34) had on average a greater reduction in IgE than the colloidal placebo group (n=33).7 On August silver 14, 1996 representatives of Broncorp, Inc. met with the Division Director, Dr. John Jenkins, and 14 other FDA officials of the Pulmonary Division at a PreNDA meeting. Dr. Mansfield made a therapies presentation on the 1995 study data (n=165) from Oregon, Washington and Idaho. He noted that together the data failed to show statistical superiority of vitamin B12 on the primary endpoint. He noted that in Washington and Idaho, during the later colloidal part silver of the study, there was a drop in the pollen counts and marked improvements in symptoms in both the vitamin B12 and placebo groups. (This made a therapeutic benefit of the B12 treatment difficult to demonstrate.) But that the pollen counts in Oregon remained higher throughout the study and that the data from therapies Oregon showed a significant difference between the active and placebo groups.8
|